Login
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc.

acumenpharm.com

What Do They Do?

Develops an investigational antibody treatment targeting amyloid-beta oligomers for people with early Alzheimer’s disease, and is also developing brain-penetrating antibody therapies for Alzheimer’s disease.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +4% (Loss)
vs −$26.5M in Q3 FY2025
  • Jun 16, 2026 Acumen exercised its option to develop two EBD candidates The candidates combine Acumen’s amyloid-beta oligomer-selective antibodies with JCR’s brain-delivery technology; one is derived from sabirnetug and the other is ACU234.

An added brain-delivery program The older report focuses on its amyloid-beta oligomer-targeting antibody; the latest report also describes a brain-penetrating therapy developed with JCR.

Subcutaneous development The older report describes intravenous development of its antibody candidate; the latest report also describes a subcutaneous formulation of sabirnetug.

Who Do They Compete With?

Competes with AbbVie, Alector, Alnylam Pharmaceuticals, AltPep, Alzheon, Alzinova, BioArctic, Biogen, Bristol-Myers Squibb, Cognition Therapeutics, Denali, Eisai, Eli Lilly, Grifols, Korsana Biosciences, Neurimmune, Priavoid, ProMIS Neurosciences, Prothena Biosciences, and Roche

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support